Medicilon Congratulates Livzon Pharmaceutical on the Approval of LiYouBao® — China’s Only Export-Qualified r-FSH Injection Meeting Global International Standards

Preclinical CRO

Livzon Pharmaceutical has secured NMPA marketing approval for LiYouBao®, its self-developed recombinant human follicle-stimulating hormone injection. The approval marks a key milestone for Livzon’s fertility pipeline, expanding its market-leading urinary FSH (u-FSH) product portfolio to build a dual u-FSH and recombinant FSH (r-FSH) technology platform. As Livzon’s trusted preclinical CRO partner, Medicilon provided integrated pharmacokinetic, […]

Medicilon Boston R&D Center Awarded Full AAALAC International Accreditation, Further Elevating Global Service Capabilities

Preclinical CRO

Recently, Medicilon Boston R&D Center has successfully passed the rigorous review by AAALAC International and achieved full AAALAC International accreditation. Following the first AAALAC accreditation of its Shanghai R&D Center back in 2009, this renewed recognition proves that Medicilon’s Boston facility has met world-class standards in laboratory animal welfare, ethical supervision, quality management and operational […]

RACI Congress 2026

Preclinical CRO

July 5-10, 2026
Perth Convention & Exhibition Centre, Perth, Western Australia
Medicilon Booth #9

EFMC-ACSMEDI 2026

Preclinical CRO

June 22-25, 2026
Trinity Conference Centre, Trinity College Dublin, Ireland

BIO 2026

Preclinical CRO

June 22-25, 2026
San Diego Convention Center

Search Medicilon

Preclinical CRO

Medicilon Webinar | IND-enabling Toxicity Studies, CTD Documentation and Translational Cardiac Risk Assessment

Preclinical CRO

Medicilon Stands Out at ASMS 2026: Only CRO Selected for Bioanalysis Zone’s ‘Pick of the Posters’

Preclinical CRO

Medicilon Congratulates Livzon Pharmaceutical on the Approval of LiYouBao® — China’s Only Export-Qualified r-FSH Injection Meeting Global International Standards

Contact Medicilon

Name(Required)
Address(Required)